Electrochemical method for producing radionuclide Lu-177 with high specific activity

Boldyrev, P. P.; Курочкин, А. В.; Nurtdinov, R. F.; Proshin, M. A.; Chuvilin, D. Yu.; Yashin, Yu. A.

doi:10.3103/s0027131416030032

Cited by 1 publication

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mAbs can specifically bind target antigens without further modifications. Significant progress has been made in the application of mAb in radioimmuno therapy (RIT). − …”

Section: Conventional Radionuclide Delivery Systemsmentioning

confidence: 99%

Transforming Nuclear Medicine with Nanoradiopharmaceuticals

et al. 2022

View full text Add to dashboard Cite

Nuclear medicine is expected to make major advances in cancer diagnosis and therapy; tumor-targeted radiopharmaceuticals preferentially eradicate tumors while causing minimal damage to healthy tissues. The current scope of nuclear medicine can be significantly expanded by integration with nanomedicine, which utilizes nanoparticles for cancer diagnosis and therapy by capitalizing on the increased surface area-to-volume ratio, the passive/active targeting ability and high loading capacity, the greater interaction cross section with biological tissues, the rich surface properties of nanomaterials, the facile decoration of nanomaterials with a plethora of functionalities, and the potential for multiplexing several functionalities within one construct. This review provides a comprehensive discussion of nuclear nanomedicine using tumor-targeted nanoparticles for cancer radiation therapy with either pre-embedded radionuclides or nonradioactive materials which can be extrinsically triggered using various external nuclear particle sources to produce in situ radioactivity. In addition, it describes the prospect of combining nuclear nanomedicine with other modalities to enable synergistically enhanced combination therapies. The review also discusses advances in the fabrication of radionuclides as well as describes laser ablation technologies for producing nanoradiopharmaceuticals, which combine the ease of production with exceptional purity and rapid biodegradability, along with additional imaging or therapeutic functionalities. From a practical standpoint, these attributes of nanoradiopharmaceuticals may provide distinct advantages in diagnostic/therapeutic sensitivity and specificity, imaging resolution, and scalability of turnkey platforms. Coupling image-guided targeted radiation therapy with the possibility of in situ activation of nanomaterials as well as combining with other therapeutic modalities using a multifunctional nanoplatform could herald an era of exciting technological and therapeutic advances to radically transform the landscape of nuclear medicine. The review concludes with a discussion of current challenges and presents the authors’ views on future opportunities to stimulate further research in this rewarding field of high societal impact.

show abstract

“…The mAbs can specifically bind target antigens without further modifications. Significant progress has been made in the application of mAb in radioimmuno therapy (RIT). − …”

Section: Conventional Radionuclide Delivery Systemsmentioning

confidence: 99%